‘Structured’ Takeover: A Bitter Pill That More Will Swallow Gladly
This article was originally published in The Pink Sheet Daily
Executive Summary
Delayed-reward setup gives pharma the edge, but can hold advantages for acquisition targets, panel says.
You may also be interested in...
J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.
FDA Panel Supports J&J’s Antibiotic Doribax With Votes, Not Confidence
An FDA panel's votes on July 16 to support Johnson & Johnson's Doribax (doripenem) reflected more the difficulty of new antibiotic drug development than the merits of J&J's particular application
Pharmos’ Synthetic Cannabinoid Disappoints In Phase IIa
Company will study oral cannabinor for neuropathic pain, adjust intravenous dosing for nociceptive pain.